**19. Future perspectives**

Despite the fact that specific antiviral medications for COVID-19 have yet to be identified or authorized by the FDA, the usage of some currently existing antiviral agents that target various phases in COVID-19's life cycle might be an alternate therapeutic strategy for combating the pandemic. Fusion inhibitors, protease inhibitors, and transcription inhibitors are just a few of the interesting antiviral medication classes to investigate. Apart from antiviral medicines, various interesting techniques to treating COVID-19 are being employed, such as convalescent plasma, which has been found to reduce viral load and patient morbidity. The effects of interferon (IFN)-α/β and IL-6R inhibitor1 have also been encouraging [126–128]. The introduction of several new technologies is likely to yield good benefits. The safety of patients should be prioritized while evaluating new SARS-CoV-2 vaccinations. Nanotechnology offers an effective new route for diagnostics and treatment techniques. The more distinctive nanoparticles operate as excellent antiviral medication delivery vehicles, increasing the procedure's effectiveness. Finding appropriate diagnostic and therapeutic strategies for the fast and efficient care of severe COVID-19 patients is urgently needed [129, 130]. Different research on different CoV-induced diseases shows that using α-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory medications might result in encouraging clinical results for SARS-Cov-2 patients. Tocilizumab should be used as a therapy approach for severe COVID-19 pneumonia to achieve favorable results. Furthermore, further clinical studies with appropriate medications should be conducted on SARS-CoV-2 patients to demonstrate effectiveness and safety.
